Novo Nordisk and Eli Lilly Report Early GLP-1 Signals of Slowed Biological Aging
Novo Nordisk and Eli Lilly presented findings at the ARDD aging research conference suggesting that GLP-1 drugs may slow biological aging. The reported signals come from company-backed research shared at the event. The source material provided is limited to a link and metadata, so the specific study design, sample size, and measured outcomes cannot be confirmed here. The results are preliminary and have not been established as definitive evidence of anti-aging effects. Further peer-reviewed research would be needed to assess the claims.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.

Discussion (0)
Log in to join the discussion and vote.
Log in